JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Organon Analyst Ratings
Russell Companies With the Lowest Tax Rates Expected to Generate $1B in 2025 – GS
Stocks With Three Weeks of Deteriorating Technicals by Piper Sandler
Organon Has Expanded Its Agreement With Eli Lilly To Become The Sole Distributor And Promoter Of The Migraine Medicine Emgality (Galcanezumab) In Additional Markets, Total Consideration To Be Paid To Lilly Includes An Upfront Payment Of $22.5M As Well...
Should Vanguard S&P Small-Cap 600 Value ETF (VIOV) Be on Your Investing Radar?
How Is The Market Feeling About Jackson Finl?
Decoding 6 Analyst Evaluations For Jackson Finl
Jackson Finl Analyst Ratings
Roth MKM Says Small-Cap Value Reaches Key Technical Support, Lists 14 "Bullish" Stocks
Jackson Financial Declares $0.70 Dividend
Jackson Finl Q2 2024 Adj EPS $3.43 Misses $4.36 Estimate, Sales $1.25B Miss $1.70B Estimate
Organon & Co Snaps Six Days of Losses
Jackson Financial Non-GAAP EPS of $5.32 Beats by $0.96, Revenue of $1.25B Misses by $450M
Here Is the Next Potential Market Catalyst
Jackson Financial Q2 2024 Earnings Preview
Organon Extends Selloff After Q2 Results
CNBC Halftime Report Final Trades: Uber Technologies, Howmet Aerospace, Organon & Co., Chipotle Mexican Grill
CORRECTION: Organon & Co. Revises FY24 Revenue Guidance From $6.2B-$6.5B To $6.25-$6.45B Vs $6.407B Est.